Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.

Chaoui D, Hacini M, Fitoussi O, Karlin L, Arkam Y, Jourdan E, Orfeuvre H, Voillat L, Sanhes L, Leprêtre S, Liu KL, Barry M, Tempescul A, Dilhuydy MS, Chaib A, Slama B, Labourey JL, Benbrahim O, Dreyfus B, Mahé B, Maynadié M, Delmer A, Benkanoun C, Boissard F, Gandon S, Veerabudun K, Choquet S, PERLE investigators

Open source

DOI: 10.1080/10428194.2018.1533130
Published: 2019 Jun
Container: Leukemia & lymphoma
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/10428194.2018.1533130,
  title = {Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.},
  author = {Chaoui D and Hacini M and Fitoussi O and Karlin L and Arkam Y and Jourdan E and Orfeuvre H and Voillat L and Sanhes L and Leprêtre S and Liu KL and Barry M and Tempescul A and Dilhuydy MS and Chaib A and Slama B and Labourey JL and Benbrahim O and Dreyfus B and Mahé B and Maynadié M and Delmer A and Benkanoun C and Boissard F and Gandon S and Veerabudun K and Choquet S and PERLE investigators},
  year = {2019},
  journal = {Leukemia \& lymphoma},
  doi = {10.1080/10428194.2018.1533130},
  url = {https://doi.org/10.1080/10428194.2018.1533130}
}

RIS

TY  - JOUR
TI  - Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.
AU  - Chaoui D
AU  - Hacini M
AU  - Fitoussi O
AU  - Karlin L
AU  - Arkam Y
AU  - Jourdan E
AU  - Orfeuvre H
AU  - Voillat L
AU  - Sanhes L
AU  - Leprêtre S
AU  - Liu KL
AU  - Barry M
AU  - Tempescul A
AU  - Dilhuydy MS
AU  - Chaib A
AU  - Slama B
AU  - Labourey JL
AU  - Benbrahim O
AU  - Dreyfus B
AU  - Mahé B
AU  - Maynadié M
AU  - Delmer A
AU  - Benkanoun C
AU  - Boissard F
AU  - Gandon S
AU  - Veerabudun K
AU  - Choquet S
AU  - PERLE investigators
PY  - 2019
JO  - Leukemia & lymphoma
DO  - 10.1080/10428194.2018.1533130
UR  - https://doi.org/10.1080/10428194.2018.1533130
ER  -

APA

D, C., M, H., O, F., L, K., Y, A., E, J., H, O., L, V., L, S., S, L., KL, L., M, B., A, T., MS, D., A, C., B, S., JL, L., O, B., B, D., B, M., M, M., A, D., C, B., F, B., S, G., K, V., S, C., & investigators, P. (2019). Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study.. Leukemia & lymphoma. https://doi.org/10.1080/10428194.2018.1533130

Source records

pubmed · retrieved 2026-09-27T14:35:29.407Z